HYPHENATED LIQUID CHROMATOGRAPHY TECHNIQUES IN CLINICAL METABOLOMICS: PRINCIPLES AND BIOMEDICAL APPLICATIONS

Clinical metabolomics refers to the rapid, broad-spectrum detection of all endogenous and environmental small-molecule metabolites in a biological system and their determination in complex biological samples. Precision medicine, biomarker discovery and personalised medicine are being advanced by this progress, much of which rests on hyphenated liquid chromatography systems, especially UHPLC-MS/MS and HRMS. Even though other methods are being developed, these remain the major platforms used to characterise the human metabolome. This review takes account of the basic principles, stationary-phase chemistries (reversed-phase and HILIC) and the ionisation interfaces that couple chromatography to mass spectrometry, together with the process safeguards clinical laboratories use to limit error from sample collection to finished analysis. This paper then looks at where these tools already impact patient care: the tracking of metabolic reprogramming in cancer; revealing disordered lipid metabolism in cardiometabolic disease; and enabling rapid newborn screening. The review concludes by examining the hurdles that remain, including cross-laboratory standardisation and what is required to advance this technology from the research bench to routine clinical use.

• Furlani IL, da Cruz Nunes E, Canuto GAB, Macedo AN, Oliveira RV. Liquid Chromatography-Mass Spectrometry for Clinical Metabolomics: An Overview. Adv Exp Med Biol., 2021; 1336: 179-213. PMID: 34628633 | DOI: 10.1007/978-3-030-77252-9_10: https://pubmed.ncbi.nlm.nih.gov/34628633/
• Dalamaga M. Clinical metabolomics: Useful insights, perspectives and challenges. Metabol Open., 2024; 22: 100290. PMID: 39011161 | DOI: 10.1016/j.metop.2024.100290:https://pubmed.ncbi.nlm.nih.gov/39011161/
• Lu J, Zhang S, Lindner JN, et al. Global Metabolomics Using LC-MS for Clinical Applications. Methods Mol Biol., 2025; 2891: 13-31. PMID: 39354299 | DOI: 10.1007/978-1-0716-4321-1_2:https://pubmed.ncbi.nlm.nih.gov/39354299/
• Pang Z, Zhou G, Chong J, Xia J. MetaboAnalystR 4.0: a unified LC-MS workflow for global metabolomics. Nat Commun., 2024; 15(1): 3642. PMID: 38693118 | DOI: 10.1038/s41467-024-48009-6:https://pubmed.ncbi.nlm.nih.gov/38693118/
• Afshar M, van Hall G. LC-MS/MS method for quantitative profiling of ketone bodies, α-keto acids, lactate, pyruvate and their stable isotopically labelled tracers in human plasma. J Chromatogr B., 2023; 1230: 123906. PMID: 37925904 | DOI: 10.1016/j.jchromb.2023.123906:https://pubmed.ncbi.nlm.nih.gov/37925904/
• Witting M. Performance comparison of narrow-bore and capillary liquid-chromatography for non-targeted metabolomics profiling by HILIC-QTOF-MS. J Chromatogr A., 2023; 1699: 463997. PMID: 37119797 | DOI: 10.1016/j.chroma.2023.463997:https://pubmed.ncbi.nlm.nih.gov/37119797/
• Januszewski AS, O'Neal DN, Jenkins AJ. Challenges and developments in tandem mass spectrometry based clinical metabolomics. Mass Spectrom Rev., 2009; 28(2): 290-305. PMID: 19007853 | DOI: 10.1002/mas.20194:https://pubmed.ncbi.nlm.nih.gov/19007853/
• Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted Metabolomics Strategies-Challenges and Emerging Directions. J Am Soc Mass Spectrom., 2016; 27(12): 1897-1905. PMID: 27624161 | DOI: 10.1007/s13361-016-1469-y:https://pubmed.ncbi.nlm.nih.gov/27624161/
• Broadhurst D, Goodacre R, Reinke SN, et al. Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics, 2018; 14(6): 72. PMID: 29805336 | DOI: 10.1007/s11306-018-1367-3:https://pubmed.ncbi.nlm.nih.gov/29805336/
• Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics, 2013; 9: 280-299: https://pubmed.ncbi.nlm.nih.gov/23543913/
• Tang DQ, Zou L, Yin XX, Ong CN. HILIC-MS for metabolomics: An attractive and complementary approach to RPLC-MS. Mass Spectrom Rev., 2016; 35(5): 574-600: https://pubmed.ncbi.nlm.nih.gov/25284160/
• Systematic evaluation of HILIC stationary phases for global metabolomics of human plasma. Metabolites, 2022; 12(2): 165: https://pubmed.ncbi.nlm.nih.gov/35208239/
• A comprehensive UHPLC-MS/MS method for metabolomics profiling of signaling lipids: markers of oxidative stress, immunity and inflammation. Anal Chim Acta (ScienceDirect). 2024: https://pubmed.ncbi.nlm.nih.gov/38438234/
• Untargeted metabolomics-based screening method for inborn errors of metabolism using semi-automatic sample preparation with an UHPLC-Orbitrap-MS platform. J Inherit Metab Dis. 2020: https://pubmed.ncbi.nlm.nih.gov/31779119/
• Optimization of sample preparation for metabolomics exploration of urine, feces, blood and saliva in humans using combined NMR and UHPLC-HRMS platforms. Molecules, 2021; 26(14): 4111: https://pubmed.ncbi.nlm.nih.gov/34299389/
• Recommendations and best practices for standardizing the pre-analytical processing of blood and urine samples in metabolomics. Metabolites. 2020: https://pubmed.ncbi.nlm.nih.gov/32503183/
• A systematic evaluation of blood serum and plasma pre-analytics for metabolomics cohort studies. PeerJ. 2016: https://pubmed.ncbi.nlm.nih.gov/27929400/
• Establishing a framework for best practices for quality assurance and quality control in untargeted metabolomics. Metabolomics, 2024; 20: 23: https://pubmed.ncbi.nlm.nih.gov/38345679/
• Annotation: a computational solution for streamlining metabolomics analysis. Anal Chem. 2018: https://pubmed.ncbi.nlm.nih.gov/29039932/
• Good practices and recommendations for using and benchmarking computational metabolomics metabolite annotation tools. Metabolomics. 2022: https://pubmed.ncbi.nlm.nih.gov/36469190/